NewsBenzingaNeurocrine Biosciences 第三季度调整后每股收益为 3.29 美元,超出 1.91 美元预期;销售额为 11.19 亿美元,超出 10.43 亿美元预期 Neurocrine Biosciences 第三季度调整后每股收益为 3.29 美元,超出 1.91 美元预期;销售额为 11.19 亿美元,超出 10.43 亿美元预期 Benzinga 2026.11.02 21:12 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3